Northwestern Mutual Wealth Management Co. Has $3.19 Million Stake in Henry Schein, Inc. $HSIC

Northwestern Mutual Wealth Management Co. increased its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 10,448.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,193 shares of the company’s stock after acquiring an additional 41,793 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Henry Schein were worth $3,189,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Artisan Partners Limited Partnership grew its position in Henry Schein by 5.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock valued at $453,509,000 after purchasing an additional 370,837 shares in the last quarter. Invesco Ltd. grew its position in Henry Schein by 4.1% in the third quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock valued at $314,043,000 after purchasing an additional 184,763 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Henry Schein by 6.5% in the third quarter. Dimensional Fund Advisors LP now owns 2,596,168 shares of the company’s stock valued at $172,304,000 after purchasing an additional 159,087 shares in the last quarter. Ameriprise Financial Inc. grew its position in Henry Schein by 11.3% in the third quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock valued at $167,453,000 after purchasing an additional 256,156 shares in the last quarter. Finally, Snyder Capital Management L P grew its position in Henry Schein by 18.6% in the third quarter. Snyder Capital Management L P now owns 1,334,364 shares of the company’s stock valued at $88,562,000 after purchasing an additional 209,123 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Morgan Stanley reaffirmed an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Leerink Partners reaffirmed a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a research report on Monday, May 4th. Mizuho decreased their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $85.00 target price (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $86.83.

Henry Schein Price Performance

Henry Schein stock opened at $74.21 on Tuesday. The firm has a market capitalization of $8.45 billion, a PE ratio of 22.42, a P/E/G ratio of 1.86 and a beta of 0.82. The company’s 50-day moving average is $74.33 and its 200-day moving average is $75.71. Henry Schein, Inc. has a fifty-two week low of $61.94 and a fifty-two week high of $89.29. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. The company had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. Henry Schein’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Sell-side analysts anticipate that Henry Schein, Inc. will post 5.31 earnings per share for the current year.

Insider Activity at Henry Schein

In other news, Director Kurt P. Kuehn sold 2,844 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the transaction, the director directly owned 15,420 shares in the company, valued at $1,217,563.20. The trade was a 15.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Mark E. Mlotek sold 5,925 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total transaction of $478,740.00. Following the transaction, the executive vice president owned 80,554 shares in the company, valued at $6,508,763.20. This represents a 6.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 105,911 shares of company stock worth $8,574,982 over the last ninety days. Company insiders own 0.89% of the company’s stock.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.